详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Application and Prospect of CRISPR/Cas9 Technology in Reversing Drug Resistance of Non-Small Cell Lung Cancer

144| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Clinical Pharmacy, Sichuan Cancer Center, School of Medicine, Sichuan Cancer Hospital and Institute, University of Electronic Science and Technology of China, Chengdu, China, [2]Personalized Drug Therapy Key Laboratory of Sichuan Province, Chengdu, China, [3]Department of Gynecology and Obstetrics, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, Chengdu, China

出处：

DOI：

ISSN：

关键词： non-small cell lung cancer drug resistance CRISPR Cas9 gene editing TKIs

摘要：

Cancer drug resistance has always been a major factor affecting the treatment of non-small cell lung cancer, which reduces the quality of life of patients. The clustered regularly interspaced short palindromic repeats/CRISPR associated protein 9 (CRISPR/Cas9) technology, as an efficient and convenient new gene-editing technology, has provided a lot of help to the clinic and accelerated the research of cancer and drug resistance. In this review, we introduce the mechanisms of drug resistance in non-small cell lung cancer (NSCLC), discuss how the CRISPR/Cas9 system can reverse multidrug resistance in NSCLC, and focus on drug resistance gene mutations. To improve the prognosis of NSCLC patients and further improve patients' quality of life, it is necessary to utilize the CRISPR/Cas9 system in systematic research on cancer drug resistance.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 2 区

医学

小类 | 2 区药学

最新[2023]版：

大类 | 2 区医学

小类 | 2 区药学

JCR分区：

出版当年[2022]版：

Q1 PHARMACOLOGY & PHARMACY

最新[2023]版：

Q1 PHARMACOLOGY & PHARMACY

影响因子： 4.4 最新[2023版] 5 最新五年平均 5.6 出版当年[2022版] 6.1 出版当年五年平均 5.988 出版前一年[2021版] 4.4 出版后一年[2023版]

第一作者：

第一作者机构： [1]Department of Clinical Pharmacy, Sichuan Cancer Center, School of Medicine, Sichuan Cancer Hospital and Institute, University of Electronic Science and Technology of China, Chengdu, China, [2]Personalized Drug Therapy Key Laboratory of Sichuan Province, Chengdu, China,

共同第一作者：

通讯作者：

通讯机构： [1]Department of Clinical Pharmacy, Sichuan Cancer Center, School of Medicine, Sichuan Cancer Hospital and Institute, University of Electronic Science and Technology of China, Chengdu, China, [2]Personalized Drug Therapy Key Laboratory of Sichuan Province, Chengdu, China,

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Application and Prospect of CRISPR/ Cas9 Technology in Reversing Drug Resistance of Non-Small Cell Lung Cancer [2]RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. [3]Cordycepin Inhibits Drug-resistance Non-small Cell Lung Cancer Progression by Activating AMPK Signaling Pathway. [4]Developing pioneering pharmacological strategies with CRISPR/Cas9 library screening to overcome cancer drug resistance [5]Characteristics, Recombination methods and Applications progresses of Split-Cas9 System [6]CRISPR-Cas9基因编辑技术用于肿瘤细胞模型的研究进展 [7]Novel ROR1 inhibitor ARI-1 suppresses the development of non-small cell lung cancer. [8]Targeted therapy of non-small cell lung cancer: mechanisms and clinical trials [9]ALK阳性非小细胞肺癌靶向治疗及其耐药机制的研究进展 [10]Publisher Correction: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer.